About Cytoki
Cytoki Leadership
Cytoki’s leadership brings together deep expertise in IL-22 biology, lipidation technology, and the discovery and clinical development of novel drugs to address metabolic disease. We are uniquely positioned to leverage the potential of IL-22 as a new treatment paradigm for metabolic diseases, including obesity, and type 2 diabetes, as well as conditions characterized by epithelial injury, such as inflammatory bowel disease (IBD).
Our team
Rasmus Jorgensen, PhD
CEO & Founder
Anne Louise Kjølbye, PhD, MBA
Chief Development Officer
Martijn van de Bunt, MD, DPhil
Chief Scientific Officer
Dorte Waaben, MSc
Head of CMC
Anuj Madhok, PhD
Head of Business Development
Karsten Skydsgaard, DVM, E*MBA
Head of Non-Clinical Development
Christian Friis
Clinical Project Leader
Our board
Christian Elling
Managing Partner, Lundbeckfonden BioCapital
Karen Wagner
Managing Partner, Ysios Capital
Dani Bach
Partner, +ND Capital
Annegret de Baey-Diepolder
Venture Partner, Seventure Partners